Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience
| Author | Dorota Zarębska-Michaluk | en |
| Author | Jerzy Jaroszewicz | en |
| Author | Ewa Janczewska | en |
| Author | Hanna Berak | en |
| Author | Andrzej Horban | en |
| Author | Marek Sitko | en |
| Author | Aleksander Garlicki | en |
| Author | Beata Dobracka | en |
| Author | Agnieszka Czauż-Andrzejuk | en |
| Author | Dorota Dybowska | en |
| Author | Waldemar Halota | en |
| Author | Małgorzata Pawłowska | en |
| Author | Magdalena Tudrujek-Zdunek | en |
| Author | Krzysztof Tomasiewicz | en |
| Author | Włodzimierz Mazur | en |
| Author | Zbigniew Deroń | en |
| Author | Teresa Belica-Wdowik | en |
| Author | Barbara Baka-Ćwierz | en |
| Author | Iwona Buczyńska | en |
| Author | Krzysztof Simon | en |
| Author | Anna Piekarska | en |
| Author | Jolanta Białkowska-Warzecha | en |
| Author | Beata Lorenc | en |
| Author | Rafał Krygier | en |
| Author | Agnieszka Staniaszek | en |
| Author | Jakub Klapaczyński | en |
| Author | Jolanta Citko | en |
| Author | Łukasz Socha | en |
| Author | Marta Wawrzynowicz-Syczewska | en |
| Author | Łukasz Laurans | en |
| Author | Robert Flisiak | en |
| Orcid | Jerzy Jaroszewicz [0000-0003-0139-4753] | en |
| Orcid | Małgorzata Pawłowska [0000-0002-6044-0425] | en |
| Issued Date | 2018-08-28 | en |
| Abstract | Background: In the interferon era, patients with HCV-related cirrhosis were considered hard to treat due to contraindications to therapy, safety issues, and poor response. Objectives: We investigated interferon-free regimens in cirrhotic patients in real-world practice. Methods: We analyzed data of HCV infected patients with liver cirrhosis conducted in 22 Polish hepatology centers. They were assigned to a treatment schedule based on physician decision. Data were collected retrospectively by an online questionnaire. Results: In total, 1113 patients infected with genotype 1 HCV were enrolled to the analysis, 96.6% presented GT1b infection. A total of 56% were treatment-experienced, mostly with PegIFN + RBV, 77.2% of group presented comorbidities with the most frequent hypertension and diabetes,73.2% patients were treated with concomitant medications, and 31% of cohort was assigned to RBV-free regimen, majority of them to OBV/PTV/r + DSV. Overall, 94.7% patients achieved the sustained virological response in intent-to-treat analysis, with comparable rate for RBV-free and RBV-containing options (94.2% vs. 94.9%). Treatment course was more often modified in RBV-containing group, whereas rate of discontinuation was the same for both cohorts. Adverse events were observed in 41% with the most common weakness/fatigue; more frequently in RBV-containing regimens (43% vs. 36.6%). Serious adverse events were reported in 4.1% patients. A total of 16 deaths not related to study drugs were documented, mostly in RBV-containing group. Conclusions: We confirmed effectiveness of the interferon-free regimens without ribavirin in real-world cohort of cirrhotic patients with chronic HCV infection genotype 1. Therapy was well tolerated with infrequent adverse events. | en |
| DOI | https://doi.org/10.5812/hepatmon.80761 | en |
| URI | https://brieflands.com/journals/hepatmon/articles/80761 | en |
| Keyword | Hepatitis C Virus | en |
| Keyword | Genotype 1 | en |
| Keyword | Liver Cirrhosis | en |
| Publisher | Brieflands | en |
| Title | Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- hepatmon-18-8-80761.pdf
- Size:
- 142.49 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF